Phaseline

Companies › Kangabio AUSTRALIA

Kangabio AUSTRALIA: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Oncology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
KGX101
Heterodimeric IL-12 prodrug with masked N-terminus and ADCC-impaired IgG1 Fc fusion
IL12, IL12RB1, IL12RB2Phase 1Advanced or Metastatic Solid TumorsJan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07260305KGX101Phase 1Advanced or Metastatic Solid TumorsOncologyJan 2027
NCT06074497KGX101Phase 1Advanced or Metastatic Solid TumorsOncologyMay 2028

Targets

IL12 (1) IL12RB1 (1) IL12RB2 (1)

Companies with the same targets

Strand Therapeutics Geneos Therapeutics Suzhou Abogen Biosciences Imunon VLP Therapeutics Sonnet BioTherapeutics enGene Inovio Pharmaceuticals Trogenix

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.